Vor Biopharma (VOR) EBIT (2020 - 2026)
Vor Biopharma (VOR) posted quarterly EBIT of -$35.2 million for Q1 2026, down 5.61% year-over-year from -$37.3 million in Q1 2025, and up 2.22% quarter-over-quarter from -$36.0 million in Q4 2025.
Vor Biopharma (VOR) EBIT (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported EBIT for 7 consecutive years, with -$35.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 5.61% year-over-year to -$35.2 million; the TTM figure through Mar 2026 stood at -$373.5 million (down 205.78% YoY), while the FY2025 annual figure was -$371.6 million, down 206.67% from the prior year.
- EBIT climbed to -$35.2 million in Q1 2026 per VOR's latest filing, from -$36.0 million in the prior quarter.
- Across five years, EBIT topped out at -$21.8 million in Q2 2022 and bottomed at -$274.3 million in Q2 2025.
- Historically, EBIT has averaged -$44.0 million across 5 years, with a median of -$30.4 million in 2023.
- Annual changes were most pronounced in 2024 — EBIT advanced 19.26% — and 2025, when it sank 844.67%.
- Vor Biopharma's EBIT stood at -$24.7 million in 2022, then decreased by 13.75% to -$28.1 million in 2023, then slipped by 11.33% to -$31.3 million in 2024, then retreated by 14.85% to -$36.0 million in 2025, then grew by 2.22% to -$35.2 million in 2026.
- Business Quant data shows VOR's EBIT at -$35.2 million in Q1 2026, -$36.0 million in Q4 2025, and -$28.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -47.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.85 Mn |
| Mar 31, 2026 | -35.16 Mn |
| Dec 31, 2025 | -35.96 Mn |
| Sep 30, 2025 | -28.11 Mn |
| Jun 30, 2025 | -274.28 Mn |
| Mar 31, 2025 | -33.29 Mn |
| Dec 31, 2024 | -31.31 Mn |
| Sep 30, 2024 | -28.51 Mn |
| Jun 30, 2024 | -29.04 Mn |
| Mar 31, 2024 | -32.33 Mn |
| Dec 31, 2023 | -28.12 Mn |
| Sep 30, 2023 | -35.32 Mn |
| Jun 30, 2023 | -32.17 Mn |
| Mar 31, 2023 | -30.42 Mn |
| Dec 31, 2022 | -24.73 Mn |
| Sep 30, 2022 | -24.10 Mn |
| Jun 30, 2022 | -21.79 Mn |
| Mar 31, 2022 | -22.80 Mn |
| Dec 31, 2021 | -18.31 Mn |
| Sep 30, 2021 | -18.60 Mn |